469 related articles for article (PubMed ID: 8551753)
1. Surface-bound heparin fails to reduce thrombin formation during clinical cardiopulmonary bypass.
Gorman RC; Ziats N; Rao AK; Gikakis N; Sun L; Khan MM; Stenach N; Sapatnekar S; Chouhan V; Gorman JH; Niewiarowski S; Colman RW; Anderson JM; Edmunds LH
J Thorac Cardiovasc Surg; 1996 Jan; 111(1):1-11; discussion 11-2. PubMed ID: 8551753
[TBL] [Abstract][Full Text] [Related]
2. Biocompatibility of heparin-coated extracorporeal bypass circuits: a randomized, masked clinical trial.
Muehrcke DD; McCarthy PM; Kottke-Marchant K; Harasaki H; Pierre-Yared J; Borsh JA; Ogella DA; Cosgrove DM
J Thorac Cardiovasc Surg; 1996 Aug; 112(2):472-83. PubMed ID: 8751516
[TBL] [Abstract][Full Text] [Related]
3. Complete heparin-coated (CBAS) cardiopulmonary bypass and reduced systemic heparin dose; effects on coagulation and fibrinolysis.
Ovrum E; Brosstad F; Am Holen E; Tangen G; Abdelnoor M; Oystese R
Eur J Cardiothorac Surg; 1996; 10(6):449-55. PubMed ID: 8817142
[TBL] [Abstract][Full Text] [Related]
4. Effects of nafamostat mesilate and minimal-dose aprotinin on blood-foreign surface interactions in cardiopulmonary bypass.
Kaminishi Y; Hiramatsu Y; Watanabe Y; Yoshimura Y; Sakakibara Y
Ann Thorac Surg; 2004 Feb; 77(2):644-50. PubMed ID: 14759453
[TBL] [Abstract][Full Text] [Related]
5. Enoxaparin suppresses thrombin formation and activity during cardiopulmonary bypass in baboons.
Gikakis N; Rao AK; Miyamoto S; Gorman JH; Khan MM; Anderson HL; Hack CE; Sun L; Niewiarowski S; Colman RW; Edmunds LH
J Thorac Cardiovasc Surg; 1998 Dec; 116(6):1043-51. PubMed ID: 9832697
[TBL] [Abstract][Full Text] [Related]
6. Reducing thrombin formation during cardiopulmonary bypass: is there a benefit of the additional anticoagulant action of aprotinin?
Dietrich W
J Cardiovasc Pharmacol; 1996; 27 Suppl 1():S50-7. PubMed ID: 8938284
[TBL] [Abstract][Full Text] [Related]
7. Cell activation and thrombin generation in heparin bonded cardiopulmonary bypass circuits using a novel in vitro model.
Bannan S; Danby A; Cowan D; Ashraf S; Gesinde M; Martin P
Eur J Cardiothorac Surg; 1997 Aug; 12(2):268-75. PubMed ID: 9288518
[TBL] [Abstract][Full Text] [Related]
8. Effects on coagulation and fibrinolysis with reduced versus full systemic heparinization and heparin-coated cardiopulmonary bypass.
Ovrum E; Brosstad F; Am Holen E; Tangen G; Abdelnoor M
Circulation; 1995 Nov; 92(9):2579-84. PubMed ID: 7586360
[TBL] [Abstract][Full Text] [Related]
9. A closed perfusion system with heparin coating and centrifugal pump improves cardiopulmonary bypass biocompatibility in elderly patients.
Lindholm L; Westerberg M; Bengtsson A; Ekroth R; Jensen E; Jeppsson A
Ann Thorac Surg; 2004 Dec; 78(6):2131-8; discussion 2138. PubMed ID: 15561050
[TBL] [Abstract][Full Text] [Related]
10. Heparin-coated bypass circuits (Carmeda) suppress the release of tissue plasminogen activator during normothermic coronary artery bypass graft surgery.
Spiess BD; Vocelka C; Cochran RP; Soltow L; Chandler WL
J Cardiothorac Vasc Anesth; 1998 Jun; 12(3):299-304. PubMed ID: 9636912
[TBL] [Abstract][Full Text] [Related]
11. Completely heparinized cardiopulmonary bypass and reduced systemic heparin: clinical and hemostatic effects.
Ovrum E; Holen EA; Tangen G; Brosstad F; Abdelnoor M; Ringdal MA; Oystese R; Istad R
Ann Thorac Surg; 1995 Aug; 60(2):365-71. PubMed ID: 7646097
[TBL] [Abstract][Full Text] [Related]
12. Activation of fibrinolysis in the pericardial cavity during cardiopulmonary bypass.
Tabuchi N; de Haan J; Boonstra PW; van Oeveren W
J Thorac Cardiovasc Surg; 1993 Nov; 106(5):828-33. PubMed ID: 8231204
[TBL] [Abstract][Full Text] [Related]
13. Heparin-coated cardiopulmonary bypass circuits: hemostatic alterations and postoperative blood loss.
Wagner WR; Johnson PC; Thompson KA; Marrone GC
Ann Thorac Surg; 1994 Sep; 58(3):734-40; discussion 741. PubMed ID: 7944696
[TBL] [Abstract][Full Text] [Related]
14. Effect of factor Xa inhibitors on thrombin formation and complement and neutrophil activation during in vitro extracorporeal circulation.
Gikakis N; Khan MM; Hiramatsu Y; Gorman JH; Hack CE; Sun L; Rao AK; Niewiarowski S; Colman RW; Edmunds LH
Circulation; 1996 Nov; 94(9 Suppl):II341-6. PubMed ID: 8901772
[TBL] [Abstract][Full Text] [Related]
15. Heparin coating of extracorporeal circuits inhibits contact activation during cardiac operations.
te Velthuis H; Baufreton C; Jansen PG; Thijs CM; Hack CE; Sturk A; Wildevuur CR; Loisance DY
J Thorac Cardiovasc Surg; 1997 Jul; 114(1):117-22. PubMed ID: 9240301
[TBL] [Abstract][Full Text] [Related]
16. Clinical study of platelet function and coagulation/fibrinolysis with Duraflo II heparin coated cardiopulmonary bypass equipment.
Nakajima T; Osawa S; Ogawa M; Sasaki T; Izumoto H; Yagi Y; Kawazoe K
ASAIO J; 1996; 42(4):301-5. PubMed ID: 8828788
[TBL] [Abstract][Full Text] [Related]
17. Limitation of thrombin generation, platelet activation, and inflammation by elimination of cardiotomy suction in patients undergoing coronary artery bypass grafting treated with heparin-bonded circuits.
Aldea GS; Soltow LO; Chandler WL; Triggs CM; Vocelka CR; Crockett GI; Shin YT; Curtis WE; Verrier ED
J Thorac Cardiovasc Surg; 2002 Apr; 123(4):742-55. PubMed ID: 11986603
[TBL] [Abstract][Full Text] [Related]
18. Thrombin generation during cardiopulmonary bypass using heparin-coated or standard circuits.
Ernofsson M; Thelin S; Siegbahn A
Scand J Thorac Cardiovasc Surg; 1995; 29(4):157-65. PubMed ID: 8789468
[TBL] [Abstract][Full Text] [Related]
19. Heparin-coated circuits reduce complement activation and inflammatory response to cardiopulmonary bypass.
Tamim M; Demircin M; Guvener M; Peker O; Yilmaz M
Panminerva Med; 1999 Sep; 41(3):193-8. PubMed ID: 10568115
[TBL] [Abstract][Full Text] [Related]
20. Cardiopulmonary bypass with heparin-coated circuits and reduced systemic anticoagulation.
Kuitunen AH; Heikkilä LJ; Salmenperä MT
Ann Thorac Surg; 1997 Feb; 63(2):438-44. PubMed ID: 9033316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
